MAZE · Insider Trading
Maze Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by MAZE officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-02 | Jason V Coloma | Chief Executive Officer | Sell | −34,501 | −$932.26K |
| 2026-10-02 | Harold Bernstein | President, R&D & CMO | MIXED | — | −$266.55K |
| 2026-10-01 | Atul Dandekar | CSBO | MIXED | — | −$124.77K |
| 2026-09-08 | Harold Bernstein | President, R&D & CMO | Sell | −9,705 | −$254.50K |
| 2026-09-04 | Phillips Courtney | GC and Corp. Secretary | Sell | −3,993 | −$104.77K |
| 2026-09-04 | Atul Dandekar | CSBO | Sell | −6,434 | −$168.81K |
| 2026-09-04 | Jason V Coloma | Chief Executive Officer | Sell | −22,638 | −$593.95K |
| 2026-09-04 | Harold Bernstein | President, R&D & CMO | Sell | −10,295 | −$270.11K |
| 2026-09-03 | Atul Dandekar | CSBO | M | +12,500 | — |
| 2026-09-03 | Harold Bernstein | President, R&D & CMO | MIXED | +20,000 | −$257.32K |
| 2026-09-03 | Jason V Coloma | Chief Executive Officer | MIXED | +15,499 | −$907.00K |
| 2026-09-03 | Phillips Courtney | GC and Corp. Secretary | M | +11,000 | — |
| 2026-08-31 | Atul Dandekar | CSBO | MIXED | — | −$128.67K |
| 2026-08-17 | Sophie Kornowski | Director | A | +36,000 deriv. | — |
| 2026-08-17 | Paula A Johnson | Director | A | +36,000 deriv. | — |
| 2026-08-14 | Harold Bernstein | President, R&D & CMO | MIXED | — | −$277.42K |
| 2026-08-05 | Jason V Coloma | Chief Executive Officer | Sell | −34,501 | −$922.32K |
| 2026-07-31 | Atul Dandekar | CSBO | MIXED | — | −$126.88K |
| 2026-07-02 | Harold Bernstein | President, R&D & CMO | MIXED | — | −$284.64K |
| 2026-07-02 | Jason V Coloma | Chief Executive Officer | Sell | −34,501 | −$1.03M |
| 2026-07-01 | Atul Dandekar | CSBO | MIXED | — | −$132.00K |
| 2026-06-24 | Jason V Coloma | Chief Executive Officer | Sell | −27,858 | −$725.49K |
| 2026-06-10 | Jonathan E Lim | Director | A | +18,000 deriv. | — |
| 2026-06-10 | Charles J Homcy | Director | A | +18,000 deriv. | — |
| 2026-06-10 | Richard H Scheller | Director | A | +18,000 deriv. | — |
| 2026-06-10 | Nancy C Andrews | Director | A | +18,000 deriv. | — |
| 2026-06-10 | Daniel K Spiegelman | Director | A | +18,000 deriv. | — |
| 2026-06-10 | Herve Hoppenot | Director | A | +18,000 deriv. | — |
| 2026-06-03 | Jason V Coloma | Chief Executive Officer | Sell | −6,643 | −$174.05K |
| 2026-06-03 | Harold Bernstein | President, R&D & CMO | MIXED | — | −$226.34K |
| 2026-06-02 | Atul Dandekar | CSBO | MIXED | — | −$119.40K |
| 2026-05-27 | Jason V Coloma | Chief Executive Officer | Sell | −32,564 | −$847.05K |
| 2026-05-18 | Harold Bernstein | President, R&D & CMO | MIXED | — | −$237.05K |
| 2026-05-18 | Jason V Coloma | Chief Executive Officer | Sell | −1,938 | −$50.39K |
| 2026-05-06 | Charles J Homcy | Director | G | −7,422 | — |
| 2026-05-06 | Atul Dandekar | CSBO | M | +14,305 | +$149.06K |
| 2026-05-01 | Atul Dandekar | CSBO | MIXED | — | −$112.15K |
| 2026-04-02 | Harold Bernstein | President, R&D & CMO | MIXED | — | −$285.60K |
| 2026-04-02 | Amy Bachrodt | SVP, Finance | MIXED | — | −$47.56K |
| 2026-04-01 | Atul Dandekar | CSBO | MIXED | — | −$141.87K |
| 2026-03-20 | Harold Bernstein | President, R&D & CMO | MIXED | — | −$580.14K |
| 2026-03-12 | Harold Bernstein | President, R&D & CMO | MIXED | — | −$1.20M |
| 2026-03-03 | Jason V Coloma | Chief Executive Officer | A | +225,000 deriv. | — |
| 2026-03-03 | Misbah Tahir | Chief Financial Officer | A | +60,000 deriv. | — |
| 2026-03-03 | Harold Bernstein | President, R&D & CMO | A | +72,000 deriv. | — |
| 2026-03-03 | Atul Dandekar | CSBO | MIXED | — | −$262.57K |
| 2026-03-03 | Phillips Courtney | GC and Corp. Secretary | A | +48,000 deriv. | — |
| 2026-03-03 | Amy Bachrodt | SVP, Finance | MIXED | — | −$173.91K |
| 2026-02-04 | Amy Bachrodt | SVP, Finance | MIXED | — | −$178.12K |
| 2026-02-04 | Harold Bernstein | President, R&D & CMO | MIXED | — | −$534.03K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| TRV GP V, LLC | 10%+ Owner | 7,024,758 | $218.26M |
| Third Rock Ventures GP V, LP | 10%+ Owner | 5,424,758 | $168.55M |
| Jonathan E Lim | Director | 328,700 | $10.21M |
| Jason V Coloma | Chief Executive Officer | 42,920 | $1.33M |
| Charles J Homcy | Director | 38,535 | $1.20M |
| Atul Dandekar | CSBO | 32,316 | $1.00M |
| Amy Bachrodt | SVP, Finance | 13,265 | $412.14K |
| Phillips Courtney | GC and Corp. Secretary | 7,029 | $218.39K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the MAZE quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.